Flares in lupus nephritis: Incidence,impact on renal survival and management

Abstract

One of the characteristics of systemic lupus erythematosus (SLE) is the large inter-and intra-individual variability of the clinical course. Lupus nephritis is no exception. Some patients with kidney involvement may show rapid progression to renal failure, others may enter complete and stable remission after adequate therapy while a number of other patients, with similar clinical and histological pattern at presentation, may alternate periods of clinical quiescence with renal exacerbations of different severity. In this paper we focus on the incidence, the prognostic significance and the treatment of renal flares in patients with SLE nephritis.

Keywords

autoimmune diseases corticosteroids immunosuppression lupus nephriti

Get full access to this article

View all access options for this article.

References

Donadio JV , Holley KE , Ferguson RH , Ilstrup DM . Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide . N Engl J Med 1978; 299: 1151–1155 .

Chan TM et al Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone . Nephron 1995; 71: 321–327 .

Ciruelo E , De la Cruz J , Lopez I , Gomez-Reino JJ . Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide . Arthritis Rheum 1996; 39: 2028–2034 .

Boumpas DT et al Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992; 340: 741–745 .

Moroni G et al ‘Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis . Kidney Int 1996; 50: 2047–2053 .

Leaker B , Fairley KF , Dowling J , Kincaid-Smith P . Lupus nephritis: clinical and pathological correlation . Q J Med 1987; 62: 163–179 .

Wagner-Weiner I , Magilavy DB , Emery HM . Flare of childhood lupus nephritis after discontinuing treatment with intravenous pulse cyclophosphamide . Arthritis Rheum 1988; 31 (Suppl. 4): abstract 102-102 .

Moroni G , Banfi G , Ponticelli C . Clinical status of patients after 10 years of lupus nephritis . Q J Med 1992; 84: 681–689 .

Chagnac A et al Outcome of the acute glomerular injury in proliferative lupus nephritis . J Clin Invest 1989; 84: 922–930 .

10.

Pollak VE , Kant KS , Hariharan S . Diffuse and focal proliferative lupus nephritis: treatment approach and results . Nephron 1991; 59: 177–193 .

11.

Ponticelli C. Treatment of lupus nephritis. The advantages of a flexible approach . Nephrol Dial Transplant 1997; 12: 2057–2059 .

12.

Esdaile JM et al The time-dependence of long-term prediction in lupus nephritis . Arthritis Rheum 1994; 37: 359–368 .

13.

Gourley MF et al Methylprednisolone and cyclophosphamide alone or in combination, in patients with lupus nephritis . Ann Intern Med 1996; 125: 549–557 .

14.

Ponticelli C. Current treatment recommendations for lupus nephritis . Drugs 1990; 40: 19–30 .

15.

Lloyd W , Shur PH . Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE) . Medicine 1981; 60: 208–217 .

16.

Coremans EM et al Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus . Am J Med 1995; 26: 595–601 .

17.

ter Borg EJ et al Measurement of increase in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus, a long-term, prospective study . Arthritis Rheum 1990; 33: 634–643 .

18.

Swaak AJG , Aarden LA , Statius van Eps LW , Feltkamp TEW . Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus . Arthritis Rheum 1979; 22: 226–235 .